EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Varoglutamstat: Inhibiting Glutaminyl Cyclase as a Novel Target of Therapy in Early Alzheimer’s Disease

Howard H Feldman, Karen Messer, Yuqi Qiu, Marwan Sabbagh, Douglas Galasko, R Scott Turner, Oscar Lopez, Amanda Smith, January Durant, Jody-Lynn Lupo, Carolyn Revta, Archana Balasubramanian und 9 weitere

Journal of Alzheimer's Disease · 18.10.2024 · 101 (s1) · S79-S93

DOI: 10.3233/jad-231126 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Alzheimer's Disease, erschienen am 18.10.2024. Verfasst von Howard H Feldman und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, University of California San Diego, La Jolla, CA, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Aminoacyltransferases. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Varoglutamstat is a first-in-class, small molecule being investigated as a treatment for early Alzheimer’s disease (AD). It is an inhibitor of glutaminyl cyclase (QC), the enzyme that post-translationally modifies amyloid-β (Aβ) peptides into a toxic form of pyroglutamate Aβ (pGlu-Aβ) and iso-QC which post-translationally modifies cytokine monocyte chemoattractant protein-1 (CCL2) into neuroinflammatory pGlu-CCL2. Early phase clinical trials identified dose margins for safety and tolerability of varoglutamstat and biomarker data supporting its potential for clinical efficacy in early AD.

Objective

Present the scientific rationale of varoglutamstat in the treatment of early AD and the methodology of the VIVA-MIND (NCT03919162) trial, which uses a seamless phase 2A-2B design. Our review also includes other pharmacologic approaches to pGlu-Aβ.

Methods

Phase 2A of the VIVA-MIND trial will determine the highest dose of varoglutamstat that is safe and well tolerated with sufficient plasma exposure and a calculated target occupancy. Continuous safety evaluation using a pre-defined safety stopping boundary will help determine the highest tolerated dose that will carry forward into phase 2B. An interim futility analysis of cognitive function and electroencephalogram changes will be conducted to inform the decision of whether to proceed with phase 2B. Phase 2B will assess the efficacy and longer-term safety of the optimal selected phase 2A dose through 72 weeks of treatment.

Conclusions

Varoglutamstat provides a unique dual mechanism of action addressing multiple pathogenic contributors to the disease cascade. VIVA-MIND provides a novel and efficient trial design to establish its optimal dosing, safety, tolerability, and efficacy in early AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAminoacyltransferasesAgedFemaleHumansMaleAmyloid beta-PeptidesRandomized Controlled Trials as TopicClinical Trials, Phase II as Topic

Stichwörter der Autor:innen

Alzheimer’s diseaseCCL2N3pE-AβQPCTQPCTLamyloid β-peptidescerebrospinal fluidglutaminyl cyclasemild cognitive impairmentpGlu-Aβ

Substanzen

AminoacyltransferasesAmyloid beta-Peptidesglutaminyl-peptide cyclotransferase

Autor:innen und Institutionen

  • Department of Neurosciences, University of California San Diego, La Jolla, CA, USA.
  • Alzheimer's Disease Cooperative Study, University of California San Diego, La Jolla, CA, USA.
  • Shiley-Marcos Alzheimer's Disease Research Center, La Jolla, CA, USA.
  • Department of Statistics, East China Normal University, Shanghai, China.
  • Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.
  • Department of Neurology, Georgetown University, Washington, DC, USA.

Förderung

  • NIA NIH HHS

Zitieren

APA

Feldman, H. H., Messer, K., Qiu, Y., Sabbagh, M., Galasko, D., Turner, R. S., Lopez, O., Smith, A., Durant, J., Lupo, J. L., Revta, C., Balasubramanian, A., Kuehn-Wache, K., Wassmann, T., Schell-Mader, S., Jacobs, D. M., Salmon, D. P., Léger, G., DeMarco, M. L., …, & ADCS VIVA-MIND Study Group (2024). Varoglutamstat: Inhibiting Glutaminyl Cyclase as a Novel Target of Therapy in Early Alzheimer’s Disease. Journal of Alzheimer's Disease, 101(s1), S79-S93. https://doi.org/10.3233/jad-231126

Vancouver

Feldman HH, Messer K, Qiu Y, Sabbagh M, Galasko D, Turner RS, et al. Varoglutamstat: Inhibiting Glutaminyl Cyclase as a Novel Target of Therapy in Early Alzheimer’s Disease. Journal of Alzheimer's Disease. 2024;101(s1):S79-S93. doi:10.3233/jad-231126

BibTeX
@article{Feldman2024,
  author = {Feldman, Howard H and Messer, Karen and Qiu, Yuqi and Sabbagh, Marwan and Galasko, Douglas and Turner, R Scott and Lopez, Oscar and Smith, Amanda and Durant, January and Lupo, Jody-Lynn and Revta, Carolyn and Balasubramanian, Archana and Kuehn-Wache, Kerstin and Wassmann, Tanja and Schell-Mader, Sylvia and Jacobs, Diane M and Salmon, David P and Léger, Gabriel and DeMarco, Mari L and Weber, Frank and ADCS VIVA-MIND Study Group, ADCS VIVA-MIND Study Group},
  title = {Varoglutamstat: Inhibiting Glutaminyl Cyclase as a Novel Target of Therapy in Early Alzheimer’s Disease},
  journal = {Journal of Alzheimer's Disease},
  year = {2024},
  volume = {101},
  number = {s1},
  pages = {S79--S93},
  doi = {10.3233/jad-231126}
}
Kostenlos starten →